Trial Profile
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 21 Jun 2018 Status changed from recruiting to discontinued.
- 11 Dec 2015 New trial record